The cardiac autonomic control market primarily consists of various devices and implants required in monitoring and regulating the autonomic functions of heart. Devices like pacemakers and implantable cardioverter defibrillators are implanted inside the body to monitor heart rate and rhythm and provide electrical stimulation as required. The growing prevalence of cardiovascular diseases worldwide has augmented the demand for continuous monitoring and automated treatment, fueling growth of the cardiac autonomic control market.
The global Cardiac Autonomic Control Market is estimated to be valued at US$ 16.84 Bn in 2023 and is expected to exhibit a CAGR of 7.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Artificial intelligence integrated with cardiac implants is becoming a new trend in the market. AI-powered pacemakers and defibrillators can learn patient’s heart pattern over time and provide treatment basis the predictive analysis. They have the potential to reduce need for device replacement by more accurately responding to arrhythmias. AI integration allows continuous remote monitoring by physicians and automated adjustments of therapy in case of irregularities, improving patient care and experience.
SWOT Analysis
Strength: Cardiac autonomic control devices offer minimally invasive treatment options and have better patient compliance compared to medications. These devices help restore autonomic balance and heart rate variability.
Weakness: High costs associated with cardiac autonomic control devices limit their adoption. Low awareness among patients and lack of reimbursement policies further challenges the market.
Opportunity: Rising geriatric population suffering from cardiovascular diseases and growing demand for minimally invasive procedures create new opportunities. Expanding applications of these devices also open up new avenues.
Threats: Stringent regulatory frameworks and long product approval timelines threaten market growth. Developing substitute treatment options also pose a threat.
Key Takeaways
The Global Cardiac Autonomic Control Market Size is expected to witness high growth over the forecast period owing to factors such as increasing obese population suffering from cardiovascular diseases and growing preference for minimally invasive surgeries.
Regional analysis
North America currently dominates the global market and is projected to maintain its lead over 2023-2030. This is attributed to factors such as rising disease burden, availability of advanced healthcare infrastructure, and supportive reimbursement systems in countries like the US and Canada. Asia Pacific is expected to witness the fastest growth owing to growing healthcare expenditure, increasing awareness, and rapidly ageing population in countries like China and India.
Key players
Key players operating in the cardiac autonomic control market are Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, Biotronik SE & Co. KG, MicroPort Scientific Corporation, LivaNova PLC, Nihon Kohden Corporation, and Schiller AG. Some of the leading players focus on expanding their geographical presence and enhancing product innovation capabilities through partnerships and mergers and acquisitions.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.